Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Mar 31;95(7):3597-602.
doi: 10.1073/pnas.95.7.3597.

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

H Yasuda  1 , N Shima, N Nakagawa, K Yamaguchi, M Kinosaki, S Mochizuki, A Tomoyasu, K Yano, M Goto, A Murakami, E Tsuda, T Morinaga, K Higashio, N Udagawa, N Takahashi, T Suda
Affiliations

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

H Yasuda et al. Proc Natl Acad Sci U S A. .

Abstract

Osteoclasts, the multinucleated cells that resorb bone, develop from hematopoietic cells of monocyte/macrophage lineage. Osteoclast-like cells (OCLs) are formed by coculturing spleen cells with osteoblasts or bone marrow stromal cells in the presence of bone-resorbing factors. The cell-to-cell interaction between osteoblasts/stromal cells and osteoclast progenitors is essential for OCL formation. Recently, we purified and molecularly cloned osteoclastogenesis-inhibitory factor (OCIF), which was identical to osteoprotegerin (OPG). OPG/OCIF is a secreted member of the tumor necrosis factor receptor family and inhibits osteoclastogenesis by interrupting the cell-to-cell interaction. Here we report the expression cloning of a ligand for OPG/OCIF from a complementary DNA library of mouse stromal cells. The protein was found to be a member of the membrane-associated tumor necrosis factor ligand family and induced OCL formation from osteoclast progenitors. A genetically engineered soluble form containing the extracellular domain of the protein induced OCL formation from spleen cells in the absence of osteoblasts/stromal cells. OPG/OCIF abolished the OCL formation induced by the protein. Expression of its gene in osteoblasts/stromal cells was up-regulated by bone-resorbing factors. We conclude that the membrane-bound protein is osteoclast differentiation factor (ODF), a long-sought ligand mediating an essential signal to osteoclast progenitors for their differentiation into osteoclasts. ODF was found to be identical to TRANCE/RANKL, which enhances T-cell growth and dendritic-cell function. ODF seems to be an important regulator in not only osteoclastogenesis but also immune system.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ODF is an OPG/OCIF-binding protein. (A) Schematic structure of ODF. Domains: C, cytoplasmic; TM, transmembrane; E, extracellular. Arrowhead represents the N terminus (Asp76) of ODF, which is fused to the C-terminal end of thioredoxin. (B) Binding analysis of [125I]OPG/OCIF to COS-7 cells transfected with the ODF expression vector (COSODF) or COS-7 cells transfected with the empty vector (COSVec). Data are expressed as mean ± SD of three cultures. (C) Coimmunoprecipitation of ODF-OPG/OCIF complexes with anti-OPG/OCIF antibody (Ab).
Figure 2
Figure 2
sODF induces OCL formation from spleen cells in the absence of osteoblasts/stromal cells. (A-C) Mouse spleen cells were cultured in the presence of 10 ng/ml of M-CSF and various concentrations of sODF for 6 days. (A) Morphology of OCLs induced from spleen cells in the presence or absence of 30 ng/ml sODF. (B) The number of TRAP-positive multinucleated cells induced by sODF. Data are expressed as mean ± SD of three cultures. (C) Autoradiography of [125I]calcitonin bound to OCLs induced by 30 ng/ml of sODF. The cells were incubated with [125I]calcitonin, stained for TRAP (Left), and processed for autoradiography (Right). (D) Resorption pits formed on a dentine slice by the induced OCLs. [Bars = 200 μm (A, C, and D).]
Figure 3
Figure 3
sODF induces OCL formation from C7 cells. (A) The number of TRAP-positive multinucleated cells induced by sODF. C7 cells were cultured in the presence of 10 ng/ml of M-CSF and various concentrations of sODF for 6 days. Data are expressed as means of two cultures. (B) Morphology of OCLs induced from C7 cells in the presence of 20 ng/ml of M-CSF and 0 or 100 ng/ml of sODF. [Bar = 200 μm.]
Figure 4
Figure 4
Expression of ODF gene. (A) A blot loaded 20 μg of total RNA from ST2 cells cultured for 4 days in the presence or absence of various concentrations of 1,25(OH)2D3 and Dex as indicated was probed with ODF or GAPDH cDNA. (B) A blot loaded 20 μg of total RNA from primary osteoblasts cultured for 6 days in the absence or presence of 10−8 M of 1,25(OH)2D3, 10−8 M of IL-11, 10−6 M of PGE2, or 5 × 10−8 M of PTH was probed with ODF or GAPDH cDNA. (C) Blots of mouse tissue poly(A)+ RNA (2 μg) were probed with ODF cDNA (Upper) or GAPDH cDNA (Lower).
Figure 5
Figure 5
A model illustrating a mechanism by which osteoblasts/stromal cells regulate osteoclastogenesis. Three distinct signals stimulated by 1,25(OH)2D3, PGE2/PTH, and IL-11 induce TRANCE/RANKL/ODF expression on osteoblasts/stromal cells. ODF mediates a signal for osteoclastogenesis through ODF receptor (RANK?) expressed on osteoclast progenitors. OPG/OCIF inhibits osteoclastogenesis by interrupting the binding of ODF and ODF receptor. M-CSF produced by osteoblasts/stromal cells is also indispensable for proliferation and differentiation of osteoclast progenitors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Suda T, Takahashi N, Martin T J. Endocr Rev. 1992;13:66–80. - PubMed
    1. Suda T, Takahashi N, Martin T J. In: Endocrine Review Monographs. Bikle D D, Negrovilar A, editors. Vol. 4. Bethesda: Endocrine Soc.; 1995. pp. 266–270.
    1. Suda T, Udagawa N, Nakamura I, Miyaura C, Takahashi N. Bone. 1995;17:87S–91S. - PubMed
    1. Roodman G D. Endocr Rev. 1996;17:308–332. - PubMed
    1. Takahashi N, Akatsu T, Uadagawa N, Sasaki T, Yamaguchi A, Moseley J M, Martin T J, Suda T. Endocrinology. 1988;123:2600–2602. - PubMed

MeSH terms

Associated data